down arrow

Intra-Cellular Therapies, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US46116X1019
USD
131.87
0.00 (0.00%)

Apr 03

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

70.90131.98
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2024)

FII

19.58%

Held by 182 FIIs

DII

26.4%

Held by 65 DIIs

Promoter

0.37%

How big is Intra-Cellular Therapies, Inc.?

22-Jun-2025

As of Apr 03, Intra-Cellular Therapies, Inc. has a market capitalization of $14.02 billion, with recent net sales of $680.86 million and a net profit of -$74.68 million. As of Dec'24, the company reported shareholder's funds of $1.15 billion and total assets of $1.37 billion.

Market Cap: As of Apr 03, Intra-Cellular Therapies, Inc. has a market capitalization of 14,021.47 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Intra-Cellular Therapies, Inc. reported net sales of 680.86 million and a net profit of -74.68 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 1,148.46 million and total assets of 1,366.91 million.

Read More

What does Intra-Cellular Therapies, Inc. do?

22-Jun-2025

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing small molecule drugs for neuropsychiatric and neurological disorders, with a market cap of approximately $14 billion. As of December 2024, it reported net sales of $199 million and a net loss of $17 million.

Overview:<BR>Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the discovery and clinical development of small molecule drugs for neuropsychiatric and neurological disorders, operating in the Pharmaceuticals: Major industry with a mid-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 199 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -17 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 14,021.47 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.01% <BR>Debt Equity: -0.87 <BR>Return on Equity: -6.50% <BR>Price to Book: 12.21<BR><BR>Contact Details:<BR>Address: 430 E 29th St, NEW YORK NY: 10016-8367 <BR>Tel: 1 212 9233344 <BR>Fax: 1 212 9233388 <BR>Website: http://www.intracellulartherapies.com/

Read More

Should I buy, sell or hold Intra-Cellular Therapies, Inc.?

22-Jun-2025

Who are in the management team of Intra-Cellular Therapies, Inc.?

22-Jun-2025

As of March 2022, the management team of Intra-Cellular Therapies, Inc. includes Dr. Sharon Mates (Chairman, President, and CEO), Mr. Robert Van Nostrand (Lead Independent Director), and Independent Directors Dr. Christopher Alafi, Dr. Richard Lerner, Mr. Joel Marcus, and Mr. Rory Riggs. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Intra-Cellular Therapies, Inc. includes the following individuals:<BR><BR>- Dr. Sharon Mates, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Mr. Robert Van Nostrand, who is the Lead Independent Director.<BR>- Dr. Christopher Alafi, Dr. Richard Lerner, Mr. Joel Marcus, and Mr. Rory Riggs, all of whom are Independent Directors.<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared Positive results for the last 12 consecutive quarters

  • OPERATING CASH FLOW(Y) Highest at USD -73.18 MM
  • NET PROFIT(HY) Higher at USD -43.21 MM
  • ROCE(HY) Highest at -8.58%
2

Risky - Not traded in last 10 days

3

High Institutional Holdings at 99.61%

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 14,021 Million (Mid Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.01%

stock-summary
Debt Equity

-0.87

stock-summary
Return on Equity

-6.50%

stock-summary
Price to Book

12.21

Revenue and Profits:
Net Sales:
199 Million
(Quarterly Results - Dec 2024)
Net Profit:
-17 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
57.51%
0%
57.51%
6 Months
82.52%
0%
82.52%
1 Year
95.89%
0%
95.89%
2 Years
141.21%
0%
141.21%
3 Years
110.39%
0%
110.39%
4 Years
286.04%
0%
286.04%
5 Years
815.76%
0%
815.76%

Intra-Cellular Therapies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
268.75%
EBIT Growth (5y)
4.43%
EBIT to Interest (avg)
-211.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.57
Tax Ratio
0.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
99.61%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.21
EV to EBIT
-111.57
EV to EBITDA
-112.06
EV to Capital Employed
86.89
EV to Sales
19.13
PEG Ratio
NA
Dividend Yield
0.01%
ROCE (Latest)
-77.88%
ROE (Latest)
-6.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 104 Schemes (53.64%)

Foreign Institutions

Held by 182 Foreign Institutions (19.58%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 50.79% vs 50.28% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 40.91% vs 35.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "199.20",
          "val2": "132.10",
          "chgp": "50.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.10",
          "val2": "-34.00",
          "chgp": "14.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.90",
          "val2": "-28.60",
          "chgp": "40.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-146.60%",
          "val2": "-258.10%",
          "chgp": "11.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 46.62% vs 85.54% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 46.53% vs 45.49% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "680.90",
          "val2": "464.40",
          "chgp": "46.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-116.20",
          "val2": "-158.90",
          "chgp": "26.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-74.70",
          "val2": "-139.70",
          "chgp": "46.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-171.40%",
          "val2": "-343.20%",
          "chgp": "17.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - YoYstock-summary
Dec'24
Dec'23
Change(%)
Net Sales
199.20
132.10
50.79%
Operating Profit (PBDIT) excl Other Income
-29.10
-34.00
14.41%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-16.90
-28.60
40.91%
Operating Profit Margin (Excl OI)
-146.60%
-258.10%
11.15%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2024 is 50.79% vs 50.28% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2024 is 40.91% vs 35.00% in Dec 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
680.90
464.40
46.62%
Operating Profit (PBDIT) excl Other Income
-116.20
-158.90
26.87%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-74.70
-139.70
46.53%
Operating Profit Margin (Excl OI)
-171.40%
-343.20%
17.18%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 46.62% vs 85.54% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 46.53% vs 45.49% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Intra-Cellular Therapies, Inc. stock-summary
stock-summary
Intra-Cellular Therapies, Inc.
Pharmaceuticals: Major
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
Company Coordinates stock-summary
Company Details
430 E 29th St , NEW YORK NY : 10016-8367
stock-summary
Tel: 1 212 9233344
stock-summary
http://www.intracellulartherapies.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."